- Home
- CHRW vs MRNA Comparison
CHRW vs MRNA Comparison
Compare CHRW & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRW
- MRNA
- Stock Information
- Founded
- CHRW 1905
- MRNA 2010
- Country
- CHRW United States
- MRNA United States
- Employees
- CHRW N/A
- MRNA N/A
- Industry
- CHRW Oil Refining/Marketing
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CHRW Consumer Discretionary
- MRNA Health Care
- Exchange
- CHRW Nasdaq
- MRNA Nasdaq
- Market Cap
- CHRW 12.2B
- MRNA 13.4B
- IPO Year
- CHRW 1997
- MRNA 2018
- Fundamental
- Price
- CHRW $116.78
- MRNA $26.12
- Analyst Decision
- CHRW Buy
- MRNA Hold
- Analyst Count
- CHRW 20
- MRNA 20
- Target Price
- CHRW $114.74
- MRNA $46.24
- AVG Volume (30 Days)
- CHRW 1.5M
- MRNA 8.1M
- Earning Date
- CHRW 07-30-2025
- MRNA 08-01-2025
- Dividend Yield
- CHRW 2.12%
- MRNA N/A
- EPS Growth
- CHRW 58.22
- MRNA N/A
- EPS
- CHRW 4.40
- MRNA N/A
- Revenue
- CHRW $17,012,580,000.00
- MRNA $3,078,000,000.00
- Revenue This Year
- CHRW N/A
- MRNA N/A
- Revenue Next Year
- CHRW $4.47
- MRNA $10.04
- P/E Ratio
- CHRW $26.57
- MRNA N/A
- Revenue Growth
- CHRW N/A
- MRNA N/A
- 52 Week Low
- CHRW $84.68
- MRNA $23.15
- 52 Week High
- CHRW $119.20
- MRNA $91.99
- Technical
- Relative Strength Index (RSI)
- CHRW 71.79
- MRNA 32.50
- Support Level
- CHRW $96.89
- MRNA $26.57
- Resistance Level
- CHRW $119.20
- MRNA $28.60
- Average True Range (ATR)
- CHRW 2.97
- MRNA 1.39
- MACD
- CHRW 1.51
- MRNA -0.90
- Stochastic Oscillator
- CHRW 89.15
- MRNA 2.37
About CHRW C.H. Robinson Worldwide Inc.
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (about 60% of net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm operates a large air and ocean forwarding division (30%), which has grown organically and via tuck-in acquisitions over the years. The remainder of revenue consists of transportation management services and a legacy produce-sourcing operation.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.